Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2013 - PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma.

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Sarcoma

Presenters

Heejung Chae

Citation

Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283

Authors

H. Chae1, J.E. Kim2, W. Kim3, J. Lee3, S.Y. Song4, M.H. Lee5, H.W. Chung5, J.S. Song6, J. Ahn1

Author affiliations

  • 1 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 2 Dept. Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 3 Department Of Orthopedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 4 Department Of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 5 Department Of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 6 Department Of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
More

Resources

Abstract 2013

Background

For liposarcoma (LPS), the mainstay of treatment is still surgical resection. Recently, some researchers suggested that immune checkpoint inhibitor may have a clinical activity in well-differentiated (WD) and dedifferentiated (DD) LPS. We aimed to evaluate the expression level of programmed death ligand 1 (PD-L1) and determine its relationship with clinical outcomes in WD/DD LPS.

Methods

All patients diagnosed with WD/DD LPS at Asan medical center from 1989 to 2017 were identified and their clinical information were obtained from our medical database. PD-L1 testing was performed with previously-collected surgery or biopsy tissue by Immunohistochemistry (IHC).

Results

Total 152 patients who were pathologically diagnosed with WD (n = 74) or DD (n = 78) LPS and had available tissue for PD-L1 IHC assay were included in this retrospective analysis. The median age was 58 years (range, 19—87) with males comprising 59.2%. By primary site, abdomen-pelvis (69.7%) was most frequently involved. Most patients (98.7%, n = 150) were presented with localized disease at the time of diagnosis and every patient with localized disease except one with high-perioperative risk (n = 149) underwent curative-intent surgical resection. PD-L1 positive (tumor proportion score ≥1%) rate was 31.1% and 51.3% in WD and DD LPS, respectively. In WD LPS, PD-L1 positivity, as well as abdomen-pelvis origin, R1/2 resection, and no adjuvant radiotherapy, was associated with shorter recurrence-free survival (RFS) (vs. PD-L1 negativity, 31.3 vs. 99.8 months; P = 0.014) and remained significant in the multivariate analysis (HR, 2.7, P = 0.028). In DD LPS, on the other hand, PD-L1 expression had no statistical significance in multivariate model for RFS. Overall survival was not properly compared due to the small number of death events.

Conclusions

Our findings indicate that decent portion of WD/DD LPS patients were positive for PD-L1 expression, and it might be a negative prognostic biomarker in surgically-resected WD LPS. This provides a rationale for future clinical trials of immune checkpoint inhibitor for patients with PD-L1-positive WD/DD LPS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.